

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal

Vortioxetine for the treatment of major depressive disorder

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Lundbeck (vortioxetine) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • Black Mental Health UK • C.A.L.M • Changes • Charlie Waller Memorial Trust • Chinese Mental Health Association • Combat Stress • Depression Alliance • Depression UK • Equalities National Council • Matthew Trust • Max Appeal • Mental Health Foundation • Mental Health Matters • Mental Health Providers Forum • MIND • Muslim Council of Britain • Muslim Health Network • National Perceptions Forum • PAPYRUS • Race Equality Foundation • Rethink Mental Health • SANE • South Asian Health Foundation • Specialised Healthcare Alliance • Together • United Response • WISH – A voice for women’s mental health • <p><u>Professional groups</u></p>	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Council for Wales • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Hafal • Journeys • Health Improvement Scotland • Medicines and Healthcare products Regulatory Agency • Mental Health Act Commission • MIND Cymru • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium • Social Care Institute for Excellence <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> • Abbott Healthcare (fluvoxamine) • Accord Healthcare (amitriptyline, citalopram, fluoxetine, quetiapine, sertraline) • Actavis (amitriptyline, citalopram, clomipramine, escitalopram, fluoxetine, fluvoxamine, imipramine, lofepramine, mirtazapine, paroxetine, quetiapine, sertraline, venlafaxine) • AMCo (amitriptyline, venlafaxine)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Association for Counselling and Psychotherapy • British Association for Psychopharmacology • British Association for Social Workers • British Association of Behavioural and Cognitive Psychotherapies • British Association of Psychotherapists • British Confederation of Psychotherapists • British Geriatrics Society • British Neuropsychiatry Association • British Psychological Society • College of Mental Health Pharmacy • College of Occupational Therapists • Counsellors and Psychotherapists in Primary Care • Clifford Beers Foundation • Health and Care Professions Council • Mental Health Nurses Association • Primary Care Mental Health Education • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Psychiatrists • Royal Pharmaceutical Society • Royal Society of Medicine • United Kingdom Clinical Pharmacy Association • United Kingdom Council for Psychotherapy <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Bedfordshire CCG • NHS Southport and Formby CCG • NHS England • Welsh Government 	<ul style="list-style-type: none"> • Apotex (citalopram) • Archimedes (phenelzine) • Arrow Generics (amitriptyline, citalopram, fluoxetine, fluvoxamine, lofepramine, mirtazapine, quetiapine, sertraline, venlafaxine) • AstraZeneca (quetiapine) • Aurobindo Pharma (citalopram, mirtazapine, paroxetine, sertraline) • Bluefish Pharmaceuticals (mirtazapine, venlafaxine) • Bristol Laboratories (citalopram, fluoxetine, sertraline, venlafaxine) • Dexcel-Pharma (venlafaxine) • Dr Reddy's Laboratories (fluoxetine, quetiapine, sertraline) • Forum Products (venlafaxine) • GlaxoSmith Kline (paroxetine) • King (nortriptyline) • Lilly (fluoxetine, duloxetine) • Lundbeck (citalopram, escitalopram) • Lupin (quetiapine, sertraline) • Marlborough (doxepin) • Medreich (mirtazapine, paroxetine, sertraline) • Merck Sharp & Dohme (mirtazapine) • Merck-Serono (lofepramine) • Milpharm Ltd (fluoxetine) • Mylan (citalopram, clomipramine, fluoxetine, lofepramine, mirtazapine, paroxetine, sertraline, venlafaxine) • Novartis (clomipramine) • Pfizer (mirtazapine, paroxetine, quetiapine, reboxetine, sertraline, venlafaxine) • Ranbaxy (amitriptyline, citalopram, fluoxetine, mirtazapine, paroxetine, quetiapine, sertraline, venlafaxine) • Rosemont Pharmaceuticals (amitriptyline, imipramine, lofepramine, mirtazapine) • Sandoz (amitriptyline, citalopram, fluoxetine, lofepramine, mirtazapine, paroxetine, quetiapine, sertraline, venlafaxine)

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Sanofi-Aventis (trimipramine) • Servier (agomelatine) • Sun Pharmaceuticals (venlafaxine) • Wockhardt (amitriptyline, fluoxetine, fluvoxamine, mirtazapine, sertraline, venlafaxine) • Zentiva (citalopram, escitalopram, fluoxetine, mirtazapine, paroxetine, quetiapine, sertraline, venlafaxine) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Campbell Collaboration Social Welfare Group • Cochrane Depression, Anxiety & Neurosis Group Institute of Psychiatry • Health Services Research Unit, Department of Public Health, University of Oxford • Institute of Psychiatry • Joseph Rowntree Foundation • MRC Clinical Trials Unit • MQ Transforming Mental Health • National Institute for Health Research • National Primary Care Research & Development Centre <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • BMJ Group • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Mental Health <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales NHS Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are:

manufacturers of comparator technologies;

Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.